Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

INVA

Innoviva Inc

Dec 20 • 04:00PM ET

17.84

Dollar change -0.09
Percentage change -0.50	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD MRK ABBV AMGN REGN BIIB BMY VRTX PFE SAN

| Held by: IJR CALF VTI IWM VB AVUV VBR VXF DFAT SPSM

Scroll to Statements

Index	RUT	P/E	25.94	EPS (ttm)	0.69	Insider Own	1.05%	Shs Outstand	62.60M	Perf Week	-3.98%
Market Cap	1.11B	Forward P/E	10.40	EPS next Y	1.72	Insider Trans	0.00%	Shs Float	61.95M	Perf Month	-6.84%
Income	64.59M	PEG	1.34	EPS next Q	0.37	Inst Own	117.34%	Short Float	17.32%	Perf Quarter	-5.66%
Sales	366.55M	P/S	3.03	EPS this Y	-80.68%	Inst Trans	-1.27%	Short Ratio	16.95	Perf Half Y	11.50%
Book/sh	10.68	P/B	1.67	EPS next Y	303.53%	ROA	5.34%	Short Interest	10.73M	Perf Year	11.71%
Cash/sh	4.18	P/C	4.26	EPS next 5Y	19.34%	ROE	9.97%	52W Range	14.32 - 21.28	Perf YTD	11.22%
Dividend Est.	-	P/FCF	6.85	EPS past 5Y	-9.02%	ROI	6.97%	52W High	-16.17%	Beta	0.54
Dividend TTM	-	Quick Ratio	1.64	Sales past 5Y	1146.35%	Gross Margin	77.52%	52W Low	24.54%	ATR (14)	0.41
Dividend Ex-Date	Sep 08, 2015	Current Ratio	1.79	EPS Y/Y TTM	23.54%	Oper. Margin	43.99%	RSI (14)	24.31	Volatility	2.26% 1.92%
Employees	112	Debt/Eq	0.67	Sales Y/Y TTM	20.48%	Profit Margin	17.62%	Recom	2.00	Target Price	19.00
Option/Short	Yes / Yes	LT Debt/Eq	0.39	EPS Q/Q	-98.04%	Payout	0.00%	Rel Volume	3.79	Prev Close	17.93
Sales Surprise	16.37%	EPS Surprise	-92.45%	Sales Q/Q	31.46%	Earnings	Nov 06 AMC	Avg Volume	633.05K	Price	17.84
SMA20	-4.88%	SMA50	-7.70%	SMA200	1.84%	Trades		Volume	2,400,707	Change	-0.50%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-18-24	Initiated	Cantor Fitzgerald	Overweight
Jul-20-22	Initiated	Goldman	Neutral	$16
Nov-20-17	Initiated	Deutsche Bank	Hold	$13

Dec-17-24 07:25AM	Innoviva enters distribution, license agreement with Basilea for Zevtera (TipRanks)
Dec-16-24 07:00AM	Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera (ceftobiprole) (Business Wire)
01:15AM	Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera (ceftobiprole) in the United States (GlobeNewswire)
Nov-26-24 07:00AM	Innoviva to Participate in the Citi 2024 Global Healthcare Conference (Business Wire)
Nov-21-24 11:14PM	Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity (PR Newswire)
04:05PM	Loading…
Nov-12-24 04:05PM	Innoviva to Participate in the UBS Global Healthcare Conference (Business Wire)
Nov-06-24 05:23PM	Innoviva: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
Sep-04-24 07:00AM	Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
Jul-31-24 10:54PM	INVA Stock Earnings: Innoviva Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:51PM	Innoviva: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
Jul-09-24 01:30PM	The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024 (InvestorPlace)
Jun-27-24 08:00AM	3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge (InvestorPlace)
Jun-18-24 09:51AM	Apple downgraded, Kroger upgraded: Wall Street's top analyst calls (The Fly)
07:00AM	Loading…
Jun-03-24 07:00AM	Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-31-24 07:30AM	3 Under-$20 Stocks That Could Make You a Fortune (InvestorPlace)
May-20-24 04:06AM	Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment (MT Newswires)
May-10-24 02:04PM	Innoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed Analysis (GuruFocus.com)
May-08-24 10:57PM	INVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:09PM	Innoviva: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
07:00AM	Innoviva to Participate in the BofA Securities Health Care Conference (Business Wire)
Apr-24-24 07:00AM	Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 (Business Wire)
Mar-04-24 04:01PM	Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva (PR Newswire)
Feb-29-24 04:56PM	Innoviva: Q4 Earnings Snapshot (Associated Press Finance)
04:37PM	Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress (Business Wire)
Feb-14-24 02:44AM	Jim Simons Bolsters Position in Innoviva Inc with Recent Acquisition (GuruFocus.com)
Jan-10-24 06:16PM	If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names (InvestorPlace)
07:03AM	Loading…
Nov-18-23 07:03AM	Insider Sell Alert: Marianne Zhen Offloads Shares of Innoviva Inc (GuruFocus.com)
Nov-03-23 06:00AM	Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 Million (GuruFocus.com)
Nov-01-23 05:32PM	Innoviva: Q3 Earnings Snapshot (Associated Press Finance) +6.92%
04:15PM	Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
04:05PM	Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea (Business Wire)
Sep-19-23 08:30AM	Innoviva to Participate in the Cantor Global Healthcare Conference (Business Wire)
Sep-18-23 08:00AM	XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults (Business Wire)
Aug-25-23 04:52PM	Innoviva Appoints Stephen Basso as Chief Financial Officer (Business Wire)
Aug-02-23 05:18PM	Innoviva: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Jul-23-23 09:22AM	Investors in Innoviva (NASDAQ:INVA) have unfortunately lost 11% over the last year (Simply Wall St.)
Jul-11-23 08:53PM	Why These 7 Stocks Are the Best Ways to Play Biotech Right Now (InvestorPlace)
08:00AM	Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics (PR Newswire)
Jul-06-23 11:33AM	12 Best Extremely Profitable Stocks to Buy (Insider Monkey)
Jun-26-23 01:27AM	Insider trades & hedge fund hits: Elliott aims to oust NRG chief (Investing.com)
Jun-21-23 08:00PM	INVA: What does Argus have to say about INVA? (Argus Research)
Jun-07-23 08:30AM	Do Its Financials Have Any Role To Play In Driving Innoviva, Inc.'s (NASDAQ:INVA) Stock Up Recently? (Simply Wall St.)
Jun-06-23 04:05PM	Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference (Business Wire)
May-24-23 01:49PM	AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter (Benzinga)
May-23-23 06:42PM	Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use (Business Wire)
May-11-23 06:45PM	Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases (Business Wire)
07:42AM	Is There An Opportunity With Innoviva, Inc.'s (NASDAQ:INVA) 35% Undervaluation? (Simply Wall St.)
May-09-23 07:45PM	Innoviva: Q1 Earnings Snapshot (AP Finance) +5.54%
04:32PM	Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Apr-28-23 05:30PM	Innoviva Announces Retirement of Board Chairman (Business Wire)
Apr-26-23 08:00PM	INVA: Lowering target price to $9.00 (Argus Research)
Apr-18-23 11:22AM	FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections (Benzinga) -5.16%
Apr-17-23 04:31PM	Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee (Business Wire)
09:40AM	Is Innoviva (INVA) Stock Undervalued Right Now? (Zacks)
09:00AM	Innoviva Stock Trading Halted Today (Business Wire)
Apr-10-23 08:38AM	Merck (MRK) Keytruda Studies in Difficult-to-Treat Cancers Fail (Zacks)
Apr-05-23 10:05AM	Pfizer (PFE) Gets FDA Acceptance for Braftovi + Mektovi sNDAs (Zacks)
09:53AM	J&J (JNJ) Offers $8.9B Settlement for Talc Cancer Lawsuits (Zacks)
Apr-03-23 12:09PM	AstraZeneca (AZN) Ultomiris Gets CHMP Nod for New Rare Disease (Zacks)
Mar-13-23 06:24PM	Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic (Business Wire)
Feb-28-23 04:10PM	Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire) -5.80%
Feb-14-23 04:33PM	11 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-13-23 05:09AM	Shareholders in Innoviva (NASDAQ:INVA) are in the red if they invested a year ago (Simply Wall St.)
Jan-23-23 11:07AM	12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds (Insider Monkey)
Jan-10-23 04:05PM	Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC (PR Newswire)
Jan-03-23 06:15PM	Innoviva (INVA) Gains As Market Dips: What You Should Know (Zacks)
Dec-28-22 06:15PM	Innoviva (INVA) Stock Moves -1.06%: What You Should Know (Zacks)
11:07AM	Do Its Financials Have Any Role To Play In Driving Innoviva, Inc.'s (NASDAQ:INVA) Stock Up Recently? (Simply Wall St.)
Dec-22-22 06:00PM	Innoviva (INVA) Gains As Market Dips: What You Should Know (Zacks)
Dec-16-22 06:00PM	Innoviva (INVA) Dips More Than Broader Markets: What You Should Know (Zacks)
Nov-30-22 04:30PM	Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR) (Business Wire)
Nov-28-22 09:40AM	Should Value Investors Buy Innoviva (INVA) Stock? (Zacks)
Nov-18-22 08:48AM	Zacks.com featured highlights PBF Energy, Innoviva, Global Partners, Heritage-Crystal Clean and Sterling Infrastructure (Zacks)
Nov-17-22 07:11AM	5 Value Stocks With Attractive EV-to-EBITDA Ratios to Snap Up (Zacks)
Nov-11-22 09:40AM	Are Investors Undervaluing Innoviva (INVA) Right Now? (Zacks)
05:29AM	Innoviva Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-09-22 06:35PM	Innoviva (INVA) Q3 Earnings and Revenues Lag Estimates (Zacks) +6.11%
04:05PM	Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire)
Oct-31-22 09:40AM	Is Bayer (BAYRY) a Great Value Stock Right Now? (Zacks)
Oct-20-22 10:02AM	Earnings Preview: Merck (MRK) Q3 Earnings Expected to Decline (Zacks)
Oct-19-22 10:01AM	Innoviva (INVA) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022 (GlobeNewswire)
Oct-14-22 12:20PM	Surging Earnings Estimates Signal Upside for Innoviva (INVA) Stock (Zacks)
Oct-12-22 08:30AM	Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022 (GlobeNewswire)
Sep-19-22 02:28PM	Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings (Benzinga)
Sep-08-22 07:00AM	Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference (Business Wire)
Sep-05-22 11:43AM	Investing in Innoviva (NASDAQ:INVA) three years ago would have delivered you a 16% gain (Simply Wall St.)
Aug-22-22 08:55AM	Innoviva Completes Acquisition of La Jolla Pharmaceutical (Business Wire)
Jul-27-22 05:55PM	Innoviva (INVA) Misses Q2 Earnings Estimates (Zacks)
04:05PM	Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire)
Jul-21-22 11:08AM	Could The Market Be Wrong About Innoviva, Inc. (NASDAQ:INVA) Given Its Attractive Financial Prospects? (Simply Wall St.)
Jul-20-22 10:01AM	Earnings Preview: Innoviva (INVA) Q2 Earnings Expected to Decline (Zacks)
Jul-14-22 06:04PM	Why 2 drug royalty deals worth close to $2 billion could signal the future (American City Business Journals)
Jul-13-22 05:29PM	Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests (Benzinga)
04:32PM	Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment (Business Wire)

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INVA

Innoviva Inc

Upgrade your FINVIZ experience